A single dose of a pharmaceutically optimized lysergide compound has produced significant, durable relief from major depressive disorder in a Phase 3 clinical trial — a milestone that could reshape how one of the world’s most common mental health conditions is treated. Definium Therapeutics announced the topline results from its Emerge trial, showing that its drug DT120 ODT met its primary endpoint and all key secondary efficacy endpoints, marking the first Phase 3 study of its kind to report results.
At a glance
- LSD-based drug: DT120 ODT is a fast-dissolving tablet containing lysergide — the tartrate salt form of LSD — formulated to rapidly activate serotonin receptors in the brain.
- Phase 3 trial: The Emerge study enrolled 149 participants aged 18 to 74 across 20 sites, all with confirmed major depressive disorder diagnoses and baseline depression scores of at least 26 on the standard MADRS scale.
- Depression relief: After six weeks, patients who received a single 100 µg dose of DT120 ODT showed a difference of 8.1 points on the MADRS scale compared to placebo, starting from a baseline score of 35.0 in the treatment group.
What makes this different
Most antidepressants require patients to take a pill every day, often for weeks before any effect appears — and many patients cycle through multiple medications without finding one that works. DT120 ODT offers a fundamentally different model: one dose, with benefits that held up over the duration of the trial.
The drug belongs to a broader wave of serotonergic psychedelics being studied for psychiatric conditions. Unlike traditional selective serotonin reuptake inhibitors (SSRIs), which adjust serotonin levels gradually over time, DT120 ODT works by rapidly binding to serotonin receptors. Definium describes it as a “pharmaceutically optimized formulation of LSD,” engineered for clinical use rather than recreational effects.
“Many patients with MDD aren’t helped by existing treatments, often experiencing partial responses, frequent medication changes, and long-term side effects,” said John Sonnenberg, Ph.D., the Emerge principal investigator, clinical psychologist, and faculty member at Northwestern University Feinberg School of Medicine. “The Emerge topline results demonstrate that a single dose of DT120 ODT can produce a meaningful and durable benefit for people with depression.”
The numbers behind the result
The Emerge trial was a randomized, double-blind, placebo-controlled study — the gold standard for clinical evidence. Participants needed a DSM-5-confirmed MDD diagnosis, a Montgomery-Åsberg Depression Rating Scale (MADRS) score of at least 26, and a Clinical Global Impression–Severity score of at least 4 at both screening and baseline.
In the treatment group of 75 participants, MADRS scores dropped significantly over six weeks against a baseline of 35.0, producing a statistically meaningful 8.1-point difference versus the 74 participants in the placebo group. The drug was well tolerated: 99% of adverse events were mild to moderate in severity and largely resolved on the day of dosing. No new safety signals emerged, and the trial showed no increase in suicidal ideation.
A growing field — with more hurdles ahead
Definium already holds Breakthrough Therapy designation from the U.S. Food and Drug Administration for DT120 ODT in generalized anxiety disorder, and the company is now advancing toward an FDA submission for the depression indication. It is also running clinical trials for post-traumatic stress disorder.
Emerge is the first of two pivotal Phase 3 studies. The second trial, called Ascend, will test both a 100 µg and a 50 µg dose alongside placebo. The lower-dose cohort is included specifically to prevent participants from accurately guessing which dose they received — a methodological precaution that strengthens the blinding design. Results from Ascend will be needed before a full regulatory submission can proceed.
Definium is not alone in this space. Johnson & Johnson, Compass Pathways, Axsome Therapeutics, and Sage Therapeutics are all developing novel depression treatments along different mechanisms. Regulatory approval for any psychedelic-based drug remains a complex and closely watched process, and Phase 3 success in one trial does not guarantee approval. The Ascend results, and the FDA review that follows, will be the real test.
Still, this is a category once dismissed by mainstream medicine that is now generating some of the most closely watched clinical data in psychiatry. The fact that a single-dose lysergide compound has cleared a rigorous Phase 3 bar — with durable effects and a clean safety profile — is a meaningful step in that longer arc. This is part of a broader pattern of advances in mental health treatment emerging from decades of renewed scientific interest in psychedelic compounds.
“These findings could support a fundamentally new approach to treating MDD for patients and providers who continue to face the limitations of existing treatment options,” said Rob Barrow, CEO of Definium Therapeutics. “Grounded in decades of scientific research, these results bring us one step closer to potentially delivering a transformative new treatment option as we advance toward FDA submission.”
Read more
For more on this story, see: Refractor — Single dose of LSD-based drug shows significant depression relief in key Phase 3 trial
For more from Good News for Humankind, see:
- Alzheimer’s risk cut in half by drug in landmark prevention trial
- Renewables now make up at least 49% of global power capacity
- The Good News for Humankind archive on mental health
About this article
- 🤖 This article is AI-generated, based on a framework created by Peter Schulte.
- 🌍 It aims to be inspirational but clear-eyed, accurate, and evidence-based, and grounded in care for the Earth, peace and belonging for all, and human evolution.
- 💬 Leave your notes and suggestions in the comments below — I will do my best to review and implement where appropriate.
- ✉️ One verified piece of good news, one insight from Antihero Project, every weekday morning. Subscribe free.
